Investors with a lot of money to spend have taken a bearish stance on Moderna MRNA.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 17 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 58%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $459,833, and 6 are calls, for a total amount of $339,091.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $110.0 for Moderna over the last 3 months.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $50.0 to $110.0, over the past month.
Moderna Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | TRADE | BULLISH | 06/21/24 | $90.00 | $91.6K | 185 | 85 |
| MRNA | PUT | TRADE | BEARISH | 03/15/24 | $110.00 | $80.5K | 601 | 35 |
| MRNA | CALL | TRADE | BULLISH | 06/21/24 | $95.00 | $74.1K | 385 | 94 |
| MRNA | CALL | TRADE | BEARISH | 02/23/24 | $97.00 | $59.8K | 3.0K | 1.0K |
| MRNA | PUT | SWEEP | BEARISH | 03/15/24 | $85.00 | $58.0K | 3.5K | 150 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
Where Is Moderna Standing Right Now?
- Trading volume stands at 2,811,480, with MRNA's price down by -0.35%, positioned at $93.33.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 13 days.
What Analysts Are Saying About Moderna
In the last month, 1 experts released ratings on this stock with an average target price of $125.0.
- An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $125.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
